Gareth Parry

Gareth Parry

Auto-generated profile, based on publicly available information

Gareth Parry

Cambridge Health Alliance, Health Evaluation Research Lab, Cambridge, United States

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2023 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
WNWynne E Norton
Wynne E Norton
AKAmy E Kennedy
Amy E Kennedy
BMBrian S Mittman
Brian S Mittman
GPGareth Parry
Gareth Parry
SSShobha Srinivasan
Shobha Srinivasan
PJPaul B Jacobsen
Paul B Jacobsen
Generating actionable research findings quickly and efficiently is critical for improving the delivery of cancer-related care and outcomes. To address this issue, the National Cancer Institute convened subject matter experts, researchers, clinicians, and patients for a 2-day virtual meeting in February 2022. The purpose of this meeting was to identify how rapid cycle interventional research methods can be used to generate findings useful in improving routine clinical practice. The meeting yielded an initial conceptualization of rapid cycle interventional research as being comprised of 6 key elements: use of iterative study designs; reliance on proximal primary outcomes; early and continued engagement with community and clinical partners; use of existing data sources to measure primary outcomes; facilitative features of the study setting and context; and consideration of appropriate rigor relative to intended use of findings. The meeting also identified the types of study designs that can be leveraged to conduct rapid cycle interventional research and provided examples of these; considered this approach from the perspective of key partners; described the clinical and data infrastructure, research resources, and key collaborations needed to support this work; identified research topics best addressed using this approach; and considered needed methodological advances. The National Cancer Institute is committed to exploring opportunities to encourage further development and application of this research approach as a means for better promoting improvements in the delivery of cancer-related care.

1 January 2021 in Journal of Central Nervous System Disease
Verified
Journal Article
Open access
PDF file
TMThomas Mathew
Thomas Mathew
KTKurian Thomas
Kurian Thomas
SJSaji K John
Saji K John
SVShruthi Venkatesh
Shruthi Venkatesh
RNRaghunandan Nadig
Raghunandan Nadig
GPGareth J Parry
Gareth J Parry
Rituximab is reserved for treating refractory myasthenia gravis (MG) patients. Here we report our experience with rituximab in AChR antibody positive generalized MG (gMG) and impending myasthenic crisis (IMC). This retrospective, observational study, conducted at a tertiary care, neuroimmunology clinic, analyzed the data of patients with AChR antibody positive gMG, treated with rituximab between 1st January 2016 and 30th October 2018. Eleven patients with AChR antibody positive gMG received rituximab. Mean age of the cohort was 50.54 ± 18.71 years with 9 males. Seven out of 11 patients received rituximab in the early stage (<2 years from onset) and had good response to treatment. Four of the 5 patients with IMC improved with rituximab alone. In the 10 patients who regularly followed up, there was a significant difference between the QMG scores at baseline and at 1, 2, 6, 12, and 18 months (P < .0001). Rituximab appears to be a potentially effective early treatment option for AChR antibody positive generalized MG and impending myasthenic crisis.

1 January 2021 in American Journal of Orthopsychiatry
Verified
Journal Article
Closed access
ADAriel M. Domlyn
Ariel M. Domlyn
JSJonathan Scaccia
Jonathan Scaccia
NLNiñon Lewis
Niñon Lewis
SCShemekka Ebony Coleman
Shemekka Ebony Coleman
GPGareth Parry
Gareth Parry
RRRohit Ramaswamy
Rohit Ramaswamy
Transforming communities to be healthier and more equitable prosents a systemic challenge best addressed by those with native knowledge of the system. Community coalitions are a promising structure for tackling local health inequities, if they approach the change process with multiple local stakeholders and with systemic change in mind. Maturity models offer a framework for system assessment by defining sequential stages toward ideal development. Providing coalitions with a structure for self-assessing community change, the Community Transformation Map (CTM) is a maturity model that operationalizes concepts hypothesized to foster systemic change. This 40-item tool encourages self-assessment, dialogue, and reconciliation of community transformation priorities via an appreciative inquiry process. The CTM was created and applied with 18 community coalitions participating in the 100 Million Healthier Lives initiative. It was iteratively drafted with representatives from across the initiative. These coalitions self-administered the CTM four times over 24 months. Coalitions used the CTM to reconcile perspectives, identify priorities, and create transformation action plans. After the fourth administration, ten semistructured interviews were conducted with coalition members. Thematic analysis revealed good contextual validity. Coalitions saw value in the CTM's productive dialogue and the shared understanding it created, but reported perceived burden in conducting repeated administration. The CTM's value is in structuring community members' reflection on complex, systemic problems. The CTM is rooted in international improvement and change principles and continues to be adapted for other change initiatives. (PsycInfo Database Record (c) 2021 APA, all rights reserved).

20 November 2024 in Psychiatry Research
Verified
Journal Article
Closed access
GPGareth J. Parry
Gareth J. Parry
LOLindsay Overhage
Lindsay Overhage
PWPeyton Williams
Peyton Williams
KHKatie Holmes
Katie Holmes
ARAkhil Reddy
Akhil Reddy
NCNicholas J. Carson
Nicholas J. Carson

24 November 2025 in JMIR Preprints
Verified
Preprint
Open access
LVLiv Valö
Liv Valö
JRJoseph Rosansky
Joseph Rosansky
GPGareth Parry
Gareth Parry
ACAlexandra Comeau
Alexandra Comeau
FRFiona Kate Rice
Fiona Kate Rice
ZSZev Schuman-Olivier
Zev Schuman-Olivier
BACKGROUND The COVID-19 pandemic highlighted a critical need for effective population mental health approaches to target the most prevalent disorders, such as depression, during periods of elevated community distress. Studies investigating the effectiveness of remotely-delivered and web-based interventions are needed to identify and innovate high-quality models for population mental health service delivery. OBJECTIVE To compare the effectiveness of two transdiagnostic treatments, Mindfulness-Based Cognitive Therapy for Resilience (MBCT-R; remotely-delivered) and iCBT (web-based), with a low-intensity control condition, CHAMindWell (CHA-MW), a web-based population health screening and stratified support program, on depression symptom severity. METHODS Participants (N=97) were randomized in a 2:2:1 ratio to MBCT-R + CHA-MW (n=37), iCBT + CHA-MW (n=41), or CHA-MW alone (n=19) in a comparative effectiveness trial occurring from May 2021 to February 2023 in an urban public safety net hospital setting. MBCT-R was an 8-session, synchronous, online group curriculum that integrated mindfulness training and cognitive behavioral therapy to address COVID-19-related psychosocial stressors associated with increased risk for depression. iCBT was a 6-session, asynchronous, individual cognitive-behavioral therapy online curriculum for depression and anxiety. Both programs were supported by and compared with CHA-MW, an integrated web-based population health monitoring and response program. MBCT-R + CHA-MW and iCBT + CHA-MW were roughly time and attention matched, while CHA-MW alone was employed as a low-intensity control condition. All study procedures, including regular mental health symptom screenings, were conducted remotely or via a web-based platform. The primary outcome was change in depression symptom severity during the 24-week study period using an intention-to-treat approach that employed generalized linear mixed effects models to evaluate the comparative effectiveness of the three intervention arms over time. Secondary and exploratory outcomes included mental health clinician visits used during the 24-week study period as well as changes in anxiety, perceived stress, interoception, experiential avoidance, emotional dysregulation, self-compassion, and decentering. RESULTS For the primary outcome, results indicated significant reductions in depression symptom severity across all treatment arms (MBCT-R mean difference=-14.1 (95% CI [-21,-7.2]; iCBT mean difference=-12.7 (95% CI [-17.4, -8.1], CHA-MW mean difference=-15.2 (95% CI [-21.8, -8.6]) but no statistically significant between-group differences. For the secondary outcome, findings indicated no statistically significant differences in mental health clinician visits by group. Exploratory analyses demonstrated statistically significant improvement in mental health outcomes across all treatment arms with no significant between-group differences. CONCLUSIONS This study demonstrated moderate to large effect size improvements in depression and exploratory mental health outcomes. However, it did not identify the superiority of any intervention, suggesting that CHA-MW, a low-intensity, resource-efficient, web-based, population mental health program, is a promising approach to mental wellness during times of high community distress with or without additional higher intensity remote interventions. CLINICALTRIAL NCT04595084

4 August 2026 in JMIR Mental Health
Verified
Journal Article
Open access
ZSZev Schuman-Olivier
Zev Schuman-Olivier
LVLiv Valö
Liv Valö
JRJoseph A Rosansky
Joseph A Rosansky
GPGareth Parry
Gareth Parry
ACAlexandra Comeau
Alexandra Comeau
CFCarl Fulwiler
Carl Fulwiler
Background: The COVID-19 pandemic highlighted a critical need for effective population mental health approaches to target the most prevalent disorders (eg, depression) during periods of elevated community distress. The effectiveness of remotely delivered and web-based interventions should be investigated to identify and innovate high-quality models for population mental health service delivery. Objective: The primary objective investigated the effectiveness of adding Mindfulness-Based Cognitive Therapy for Resilience (MBCT-R)—a live, online, synchronous, remotely delivered, group-based intervention—to Cambridge Health Alliance MindWell (CHA-MW), a web-based population health screening and stratified support program, compared with CHA-MW alone, on depression symptom severity. The secondary objective evaluated adding internet Cognitive Behavioral Therapy (iCBT)—an asynchronous, web-based, individual, digital intervention—to CHA-MW, compared with CHA-MW alone. Methods: Participants (N=97) were randomized in a 2:2:1 ratio to receive MBCT-R+CHA-MW (n=37), iCBT+CHA-MW (n=41), or CHA-MW alone (n=19) in a 3-arm randomized clinical trial, from May 2021 to September 2022 in an urban public safety net hospital outpatient setting. CHA-MW served as a low-intensity control condition. For the MBCT-R+CHA-MW arm, MBCT-R was an 8-session program mildly adapted from MBCT to address COVID-19–related risks for depression. For the iCBT+CHA-MW arm, iCBT was a 6-session curriculum added to CHA-MW. All study procedures, including regular mental health symptom screenings, were conducted remotely or via a web-based platform. The primary outcome was change in depression symptom severity during the 24-week study period using an intention-to-treat approach that used generalized linear mixed-effects models to evaluate the comparative effectiveness of MBCT-R+CHA-MW vs CHA-MW over time. A secondary analysis compared iCBT+CHA-MW vs CHA-MW on depression severity. Completer analyses were conducted (per-protocol 6+ sessions). The secondary outcome was mental health visit utilization frequency during the study period. Results: Both MBCT-R+CHA-MW (mean difference −14.1, 95% CI −21.0 to −7.2) and CHA-MW (mean difference −15.2, 95% CI −21.8 to −8.6) had significant reductions in depression symptom severity, with no statistically significant between-group differences. iCBT+CHA-MW (mean difference −12.7, 95% CI −17.4 to −8.1) also reduced depression symptoms but without between-group differences when compared with CHA-MW. Intervention completion rates were low (MBCT-R: 30% and iCBT: 24%), and completers demonstrated significantly greater reductions in depression severity than noncompleters (mean difference −8.5, 95% CI −16.2 to −0.8). Overall mental health clinician visits by group had no statistically significant differences. CHA-MW had the largest increase in participants with new psychopharmacology treatment visits during the 24-week study (CHA-MW +21%, MBCT-R +10%, and iCBT −5%). Conclusions: MBCT-R+CHA-MW, iCBT+CHA-MW, and CHA-MW were each effective in treating depression, without any intervention demonstrating superiority in intention-to-treat analyses. CHA-MW was as efficacious during the COVID-19 pandemic as more resource-intensive interventions that demanded greater time and effort from participants. Low completion rates for MBCT-R and iCBT during the COVID-19 pandemic may have contributed to these results.